Scarica l'app Stockscreener
12.59
1.48%
-0.265
Precedente Chiudi:
$12.85
Aprire:
$12.93
Volume 24 ore:
202.93K
Relative Volume:
1.40
Capitalizzazione di mercato:
$79.92M
Reddito:
-
Utile/perdita netta:
$-14.56M
Rapporto P/E:
-0.7482
EPS:
-16.82
Flusso di cassa netto:
$-12.46M
1 W Prestazione:
+3.86%
1M Prestazione:
+22.91%
6M Prestazione:
+119.79%
1 anno Prestazione:
+95.37%
Intervallo 1D:
$12.40
$13.37
Intervallo di 1 settimana:
$10.94
$14.02
Portata 52W:
$4.63
$14.22
Tenax Therapeutics Inc Stock (TENX) Company Profile
Nome
Tenax Therapeutics Inc
Settore
Industria
Telefono
919-855-2100
Indirizzo
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Confronta TENX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
12.80 | 80.23M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.76 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
809.10 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.35 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
796.92 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.03 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | Piper Sandler | Overweight |
| 2024-10-24 | Iniziato | Leerink Partners | Outperform |
| 2024-10-14 | Iniziato | Guggenheim | Buy |
| 2024-09-30 | Iniziato | William Blair | Outperform |
| 2017-05-18 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | Iniziato | MLV & Co | Buy |
| 2014-11-18 | Iniziato | WallachBeth | Buy |
Mostra tutto
Tenax Therapeutics Inc Borsa (TENX) Ultime notizie
Is Tenax Therapeutics Inc. stock near bottom after declineWeekly Trend Report & Low Volatility Stock Suggestions - ulpravda.ru
What is the fair value of Tenax Therapeutics Inc. stock nowEarnings Performance Report & Real-Time Buy Signal Notifications - ulpravda.ru
Precision Trading with Tenax Therapeutics Inc. (TENX) Risk Zones - Stock Traders Daily
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Tenax Therapeutics Inc. (TENX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Tenax Therapeutics Inc. (TENX) Affects Rotational Strategy Timing - Stock Traders Daily
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Tenax Therapeutics (TENX) Price Target Increased by 12.22% to 25.76 - Nasdaq
Will Tenax Therapeutics Inc. stock see insider buying2025 Trading Recap & Verified High Yield Trade Plans - DonanımHaber
Is Tenax Therapeutics Inc. stock overvalued by current metricsJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - DonanımHaber
Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX) - The Globe and Mail
Is Tenax Therapeutics Inc. stock supported by strong cash flowsMarket Movers & Low Drawdown Investment Ideas - DonanımHaber
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Can Tenax Therapeutics Inc. stock beat market expectations this quarter2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Guggenheim Maintains Tenax Therapeutics (TENX) Buy Recommendation - Nasdaq
Tenax Therapeutics’ phase 3 LEVEL study confirms enrollment target By Investing.com - Investing.com Canada
[8-K] TENAX THERAPEUTICS, INC. Reports Material Event | TENX SEC FilingForm 8-K - Stock Titan
Tenax Therapeutics (TENX) Updates on Clinical Trials and New Ini - GuruFocus
Tenax Therapeutics’ phase 3 LEVEL study confirms enrollment target - Investing.com
Tenax Therapeutics level trial on track to complete enrollment in H1 2026 - marketscreener.com
Tenax Therapeutics Confirms Enrollment Target for LEVEL Study; Initiates LEVEL-2 Phase 3 Study for TNX-103 - Quiver Quantitative
Tenax Therapeutics Level Trial On Track To Complete Enrollment In H1 2026 - TradingView — Track All Markets
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - The Manila Times
Heart failure drug trials expand as Tenax starts second Phase 3 study - Stock Titan
Tenax Therapeutics stock price target raised to $25 from $14 at Guggenheim - Investing.com Canada
Tenax Therapeutics (TENX): Analyst Raises Target Price to $25 | - GuruFocus
Growth Report: Is YETI stock recession proof2025 Buyback Activity & Safe Entry Zone Tips - moha.gov.vn
Discipline and Rules-Based Execution in TENX Response - Stock Traders Daily
What analysts say about Tenax Therapeutics Inc stockCovered Call Writing & Build Winning Strategies With Zero Cost - earlytimes.in
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Tenax Therapeutics Inc - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Insider Stuart Rich Buys 2,500 Shares - MarketBeat
Tenax Therapeutics director Rich Stuart buys $50,792 in stock By Investing.com - Investing.com South Africa
Tenax Therapeutics director Rich Stuart buys $50,792 in stock - Investing.com
Officer/Dir Rich Buys 5,000 ($50.8K) Of Tenax Therapeutics Inc [TENX] - TradingView — Track All Markets
TENAX Therapeutics CMO Stuart Rich Acquires 5,000 Shares - TradingView — Track All Markets
Tenax Therapeutics (NASDAQ:TENX) Insider Stuart Rich Buys 1,500 Shares - MarketBeat
Officer/Dir Rich Buys 5,000 ($45.6K) Of Tenax Therapeutics Inc [TENX] - TradingView
What technical signals suggest for Tenax Therapeutics Inc. stock2025 Macro Impact & Short-Term High Return Strategies - Newser
Behavioral Patterns of TENX and Institutional Flows - Stock Traders Daily
Why Tenax Therapeutics Inc. stock could benefit from AI revolution2025 Trading Volume Trends & Comprehensive Market Scan Insights - Newser
Financial Analysis: Mainz Biomed (NASDAQ:MYNZ) vs. Tenax Therapeutics (NASDAQ:TENX) - Defense World
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
What analysts say about Tenax Therapeutics Inc. stockMean Reversion Trades & Market-Leading Growth Rates - earlytimes.in
Tenax Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Tenax Therapeutics (Nasdaq: TENX) plans Dec. 2 and 4 fireside chats at Evercore, Piper - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
(TENX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
GIORDANO CHRISTOPHER THOMAS Insider Trades - Nasdaq
Is Tenax Therapeutics Inc. stock a safe buy before earningsEarnings Growth Report & Reliable Volume Spike Trade Alerts - newser.com
Tenax Therapeutics Inc Azioni (TENX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tenax Therapeutics Inc Azioni (TENX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
5.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):